Treatment of recurrent epithelial ovarian cancer

References

• BristowRESurvival effect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysisJ Clin Oncol2002201248125911870167
   PubMed Web of Science ®Google Scholar
• du BoisAQuinnMThigpenTfor the Gynecologic Cancer IntergroupAGO-OVARANZGOGEORTCGEICOGINECOGOGJGOGMRC/NCRINCIC-CTGNCI-USNSGORTOGSGCTGIGCSOrganizational team of the two prior International OCCC2004consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Ann Oncol200516Suppl 8viii7viii12
   Google Scholar
• RubinSCRandallTCArmstrongKAChiDSHoskinsWJTen-year follow-up of ovarian cancer patients after second-look laparotomy with negative findingsObstet Gynecol19999321249916949
   PubMed Web of Science ®Google Scholar
• MarkmanMReichmanBHakesTResponses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatinJ Clin Oncol19919180118051919630
   PubMed Web of Science ®Google Scholar
• ParmarMKLedermannJAColomboNICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR- 2.2 trialLancet20033612099210612826431
   PubMed Web of Science ®Google Scholar
• PfistererJVergoteIDu BoisAEisenhauerEAGO-OVAR, NCIC CTG, EORTC GCGCombination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInt J Gynecol Cancer200515Suppl 1364115839957
   PubMed Web of Science ®Google Scholar
• TummalaMKMcGuireWPRecurrent ovarian cancerClin Adv Hematol Oncol2005372373616224447
   PubMedGoogle Scholar
• VermorkenJBHarperPGBuyseMThe role of anthracyclines in epithelial ovarian cancerAnn Oncol199910Suppl 1435010219452
   PubMed Web of Science ®Google Scholar
• LückHJDu BoisAWeberBAGO-GINECO IntergroupThe integration of anthracyclines in the treatment of advanced ovarian cancerInt J Gynecol Cancer200111Suppl 1343811489001
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJAMayerARProlonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol1998164054109469322
   PubMed Web of Science ®Google Scholar
• ten Bokkel HuininkWGoreMCarmichaelJTopotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancerJ Clin Oncol19951521832193
   Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol2001193312332211454878
   PubMed Web of Science ®Google Scholar
• O’ByrneKJBlissPGrahamJDA phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer [abstract 808]Proc Am Soc Clin Oncol200221203a
   Google Scholar
• LundBHansenOPTheiladeKPhase II study of gemcitabine (29,29 difluorodeoxycytidine) in previously treated ovarian cancer patientsJ Natl Cancer Inst199486153015337932808
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group studyJ Clin Oncol2007255165517118024863
   PubMed Web of Science ®Google Scholar
• GordonANFinklerNEdwardsRPEfficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter studyInt J Gynecol Cancer200515578579216174225
   PubMed Web of Science ®Google Scholar
• FriedlanderMHancockKCBenignoBPazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II studyJ Clin Oncol200725suppl289s
   Google Scholar
• UzielyBJeffersSIsacsonRLiposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studiesJ Clin Oncol199513177717857602367
   PubMed Web of Science ®Google Scholar
• VaageJBarbera-GuillemEAbraRTissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenograftsCancer199473147814848111716
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol200826689089618281662
   PubMed Web of Science ®Google Scholar
• SehouliJStengelDOskay-OezcelikGNonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study GroupJ Clin Oncol200826193176318218591555
   PubMed Web of Science ®Google Scholar
• TambaroRGreggiSIaffaioliRVAn escalating dose finding study of liposomal doxorubicin and or the treatment of refractory or resistant epithelial ovarian cancerAnn Oncol2003141406141112954580
   PubMed Web of Science ®Google Scholar
• D’AgostinoGFerrandinaGLudovisiMPhase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerBr J Cancer2003891180118414520442
   PubMed Web of Science ®Google Scholar
• MonkBJHerzogTKayeSA randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). (LBA1)Ann Oncol200819Supplement 8viii1viii4
   Google Scholar
• MarkmanMBlessingJRubinSCPhase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group studyGynecol Oncol2006101343644016325893
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWChenXPhase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group StudyClin Cancer Res2005115539554816061871
   PubMed Web of Science ®Google Scholar
• FongPCBossDSCardenCPAZD281 (KU-0059436) A PARP (poly ADP-Ribose-polymerase) inhibitor with single-agent anticancer activity in patient with BRCA deficient ovarian cancer: results from a phase 1 study [abstract]J Clin Oncol2008265510
   Web of Science ®Google Scholar
• Benedetti PaniciPDe VivoABellatiFSecondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancerAnn Surg Oncol20071431136114217195909
   PubMed Web of Science ®Google Scholar
• HarterPdu BoisAHahmannMArbeitsgemeinschaft Gynaekologische Onkologie Ovarian CommitteeAGO Ovarian Cancer Study GroupSurgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialAnn Surg Oncol200613121702171017009163
   PubMed Web of Science ®Google Scholar
• PignataSDe PlacidoSBiamonteRResidual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective studyBMC Cancer20066516398939
   PubMed Web of Science ®Google Scholar
• FerreroJMWeberBGeayJFSecond-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialAnn Oncol200718226326817108151
   PubMed Web of Science ®Google Scholar
• Åvall-LundqvistEWimbergerPGladieffLPegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study [abstract]J Clin Oncol200826suppl5565
   Web of Science ®Google Scholar
• BookmanMAExtending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapyOncologist19994879410337378
   PubMedGoogle Scholar
• RosePGMossbrugerKFuscoNSmrekarMEatonSRodriguezMGemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinomaGynecol Oncol2003881172112504621
   PubMed Web of Science ®Google Scholar
• HorowitzNSHuaJGibbRKMutchDGHerzogTJThe role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro modelGynecol Oncol2004941677315262121
   PubMed Web of Science ®Google Scholar
• KatzEJVickJSKlingKMEffect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cellsEur J Cancer1990267247272168194
   PubMed Web of Science ®Google Scholar
• PignataSFerrandinaGScarfoneGExtending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective StudyOncology20067156320326
   Web of Science ®Google Scholar